How much does spravato cost?

How does Spravato compare in price to other depression treatments?

Spravato is an esketamine nasal spray approved for treatment-resistant depression. Its price varies significantly depending on the treatment phase. Induction requires two doses per week for four weeks, followed by a maintenance phase with weekly or biweekly sessions. The list price sits at about $590 for a single dose. During induction, costs can reach $4,720 per month without insurance coverage.

Spravato requires administration in a certified healthcare setting, which adds facility fees ranging from $200 to 500 per visit. These visits also include vital sign monitoring and two-hour observation periods. The combined cost for induction phase treatment is often between $5,000 and $10,000 per month.

How does insurance coverage affect Spravato pricing?

Many private insurers cover Spravato under behavioral health benefits. Coverage decisions hinge on prior authorization and documentation of failed treatments with two or more standard antidepressants. Medicare and Medicaid programs cover Spravato under certain conditions, but coverage varies by state and plan. Coverage often limited to patients who failed two or more standard antidepressants.

How much does Spravato cost without insurance?

Patients without insurance must self-pay. List price for each dose is $590. Induction requires eight doses over four weeks, so total costs before facility fees add up to $4,720. Maintenance phase requires fewer doses, but costs still remain high. Patients can access assistance programs through the manufacturer or foundations to help offset costs.

When does Spravato's patent expire?

Spravato's primary U.S. patent expires in 2034. This is confirmed by records on DrugPatentWatch.com. [1] Primary compound patents expire in 2034, primary composition of matter patents expire in 2034. Primary method-of-use patents expire in 2030. Primary use patents expire in 2030.